FTSE MIB
34.154,02 +214,27 (+0,63%) Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
84,11 +0,54 (+0,65%) Bitcoin EUR
59.863,27 +204,46 (+0,34%)
Karolinska Development AB (publ) (0P3C.L)
- GlobeNewswire
Karolinska Development’s portfolio company PharmNovo reports positive results from a clinical phase 1 study of drug candidate PN6047
STOCKHOLM, SWEDEN, October 2, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company PharmNovo has successfully completed its clinical phase 1 study with PN6047, a drug candidate developed as a potential treatment for neuropathic pain. The results from the study show that PN6047 is safe and well-tolerated at doses predicted to have clinically relevant effects. Furthermore, PN6047 seems to offer a different safety profile compared to conventional opioids. Ph
- GlobeNewswire
Karolinska Development’s portfolio company PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief for its candidate drug PN6047
STOCKHOLM, SWEDEN, September 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company PharmNovo has reported promising results in a preclinical study of the company’s drug candidate PN6047. The results reaffirm existing safety profile data of PN6047, which is planned to enter clinical phase 2 trials in 2024. PharmNovo is developing a novel treatment for nerve pain, a difficult-to-treat form of pain that often develops into a chronic condition. The company
- GlobeNewswire
Karolinska Development's portfolio company OssDsign raises SEK 150 million and makes strategic move to become a pure play orthobiologics company
STOCKHOLM, SWEDEN, September 27, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign successfully has completed a directed share issue to a value of approximately SEK 150 million. The net proceeds will be used to finance a strategic shift to fully focus its operations on the orthobiologic business in the U.S., in light of the extraordinary commercial performance of its high-margin nanosynthetic bone graft OssDsign Catalyst. The new strategy anno
